OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) announced that its promoter entity, Tenshi Pharmaceuticals Private Limited, has acquired 200,000 equity shares of the company from the open market on January 28, 2026. This acquisition represents 0.17% of the total equity share capital of OneSource Specialty Pharma Limited. The disclosure has been made as per Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
